Baxter International Inc.

Find Ratings Reports
BAX : NYSE : Health Technology
$67.06 up 0.02 | 0.03%
Today's Range: 66.8976 - 68.34
Avg. Daily Volume: 3046000.0
02/21/18 - 3:59 PM ET

Financial Analysis


BAXTER INTERNATIONAL INC's gross profit margin for the fourth quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY17 Q4 FY16
Net Sales ($mil)2774.02645.0
EBITDA ($mil)0.0556.0
EBIT ($mil)378.0368.0
Net Income ($mil)-71.0243.0


Balance Sheet Q4 FY17 Q4 FY16
Cash & Equiv. ($mil)0.02801.0
Total Assets ($mil)0.015546.0
Total Debt ($mil)0.02782.0
Equity ($mil)0.08290.0


Profitability Q4 FY17 Q4 FY16
Gross Profit Margin42.8350.17
EBITDA Margin0.021.02
Operating Margin13.6313.91
Sales Turnover0.00.65
Return on Assets0.031.93
Return on Equity0.059.9
Debt Q4 FY17 Q4 FY16
Current Ratio0.02.4
Debt/Capital0.00.25
Interest Expense0.020.0
Interest Coverage0.018.4


Share Data Q4 FY17 Q4 FY16
Shares outstanding (mil)544.63539.61
Div / share0.160.13
EPS-0.110.44
Book value / share0.015.36
Institutional Own % n/a n/a
Avg Daily Volume3156756.02247481.0

Valuation


BUY. The current P/E ratio indicates a significant discount compared to an average of 106.37 for the Health Care Equipment & Supplies industry and a significant premium compared to the S&P 500 average of 25.51. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, BAXTER INTERNATIONAL INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
BAX 50.72 Peers 106.37   BAX NA Peers 51.45

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

BAX is trading at a significant discount to its peers.

 

Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.

Ratio not available.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
BAX 21.20 Peers 26.79   BAX NM Peers 0.85

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

BAX is trading at a discount to its peers.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

BAX's negative PEG ratio makes this valuation measure meaningless.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
BAX NA Peers 5.71   BAX -85.43 Peers -2.55

Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

Ratio not available.

 

Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

However, BAX is expected to significantly trail its peers on the basis of its earnings growth rate.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
BAX 3.43 Peers 5.74   BAX 3.91 Peers 16.53

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

BAX is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

BAX significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades